FAZIPRUMIG
UNII GUY829982A

Substance Identification & Data

This profile provides standardized clinical and technical data for Faziprumig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) GUY829982A.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3059485-32-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

GUY829982A

CAS Registry Number

3059485-32-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

FAZIPRUMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C226361

National Cancer Institute reference terminology for clinical and research data.

INN ID

13955

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Faziprumig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Faziprumig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Faziprumig

Common Names & Synonyms

IG single chain VH-scFvkh-scFvkh humanized (1-625) [VH anti-ALB humanized (Homo sapiens IGHV3-23*04 (90.6%) -(IGHD) -IGHJ1*01 (80.0%) W118>S (105), G119>S (106), CDR-IMGT [8.8.8] (26-33.51-58.97-104)) (1-115) -9-mer tetraglycyl-seryl-triglycyl-seryl linker (116-124) -scFvkh anti-CD19 humanized (125-365) [V-KAPPA (Homo sapiens IGKV3D-11*02 (85.9%) -IGKJ2*02 (100%), CDR-IMGT [5.3.9] (151-155.173-175.212-220)) (125-230) -15-mer tris(tetraglycyl-seryl) linker (231-245) -VH (Homo sapiens IGHV4-30-4*09 (82.8%) -IGHD -IGHJ4*01 (100%), CDR-IMGT [10.7.12] (271-280.298-304.343-354)) (246-365)] -9-mer tetraglycyl-seryl-triglycyl-seryl linker (366-374)-scFvkh anti-CD3E humanized (375-625) [V-KAPPA (Homo sapiens IGKV4-1*01 (91.9%) -IGKJ4*01 (100%), CDR-IMGT [12.3.8] (401-412.430-432.469-476)) (375-486) -20-mer tetrakis(tetraglycyl-seryl) linker (487-506) -VH (Homo sapiens IGHV1-3*01 (86.7%) -IGHD -IGHJ3*01 (85.7%) M123>L (620), CDR-IMGT [8.8.12] (532-539.557-564.603-614)) (507-625)], produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, non-glycosylated

Immunoglobulin, trispecific, anti-(human albumin) (human-Lama glama monoclonal ALB8 single-domain VHH fragment) fusion protein with peptide linker (GGGGSGGGS) fusion protein with immunoglobulin anti-(human CD19 antigen) (human-Mus musculus monoclonal hBU12 single-chain variable fragment VL-(GGGGS)<sub>3</sub>-VH) fusion protein with peptide linker (GGGGSGGGS) fusion protein with immunoglobulin anti-(human CD3 antigen ε-chain) (human-Mus musculus monoclonal ADI-26906 single-chain variable fragment VL-(GGGGS)<sub>4</sub>-VH)

faziprumig [INN]

immunoglobulin single chain VH-scFvkh-scFvkh, anti-[Homo sapiens ALB (albumin, human serum albumin, HSA)], anti-[Homo sapiens CD19 (B lymphocyte surface antigen B4, Leu-12)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], humanized monoclonal antibody, trispecific (faziprumig)

External Clinical & Regulatory Resources

Previous UNIIGUY7697BLX

Next UNIIGUZ22Q6Y29